Legal Status Overview
Gray AreaPeptides occupy a legal gray zone in Vermont because the state has no statute or Board of Pharmacy rule that names peptides, research chemicals, or research-use-only compounds as a distinct regulatory category. Instead, Vermont's Board of Pharmacy regulates all drug compounding, sale, and dispensing under Title 26, Chapter 36, which incorporates and defers to the federal FDA compounding framework (Sections 503A and 503B of the FD&C Act). This means an FDA-approved peptide drug (like a prescribed semaglutide product) is legal with a valid prescription filled by a licensed Vermont pharmacy, while unapproved research peptides such as BPC-157 or TB-500 are governed by shifting FDA bulk-substance eligibility rules rather than any Vermont-specific ban or permission.
Key Points
- Vermont has no statute or administrative rule that names 'peptides,' 'research chemicals,' or 'research-use-only compounds' as a distinct legal category; the Vermont Board of Pharmacy's authority instead covers regulation of the sale, compounding, administration, and dispensing of medications and drugs generally under 26 V.S.A. Chapter 36. [1]
- Vermont's Board of Pharmacy Administrative Rules, effective February 1, 2026, define compounding pharmacies and 503B outsourcers using the same federal 503A/503B compounding framework used nationwide, without a peptide-specific carve-out. [2]
- Vermont compounding pharmacies operate under the federal 503A/503B distinction, meaning a 503A pharmacy may compound a peptide drug for an individual patient only from a permitted bulk drug substance and pursuant to a valid patient-specific prescription. [5]
- The FDA placed BPC-157 into Category 2 of its 503A bulk drug substances list in September 2023 over safety and impurity concerns, which barred U.S. compounding pharmacies, including any operating in Vermont, from legally compounding it during that period. [6]
- On April 15, 2026 the FDA removed BPC-157 and TB-500, along with ten other peptides, from Category 2 of the bulks list, but this does not make them FDA-approved drugs and their final compounding eligibility remains under Pharmacy Compounding Advisory Committee review. [8]
- A person cannot lawfully buy or import research-use-only BPC-157 or TB-500 for personal human use in Vermont because both remain unapproved new drugs under federal law regardless of a person's location in the state; a federal criminal case against a Kentucky compounder over unapproved peptide sales, including BPC-157, illustrates enforcement risk. [9]
- GLP-1 peptide drugs (semaglutide/tirzepatide) are legal in Vermont only as FDA-approved brand-name prescription medicines or as compounded versions prepared consistent with FDA guidance addressing supply shortages, following the FDA's April 27, 2023 letter to NABP clarifying that the approved products' active ingredient is semaglutide in its base form. [10]
- No Vermont-specific legislation, Board of Pharmacy bulletin, or Attorney General guidance addressing peptides, research chemicals, or compounded GLP-1/BPC-157-type products was found in a review of recent (2023-2026) Vermont bill-tracking and rulemaking records, indicating Vermont currently defers entirely to the general federal compounding and drug-approval framework for this category. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in Vermont
| BPC-157 | BPC-157 is not FDA-approved and has no Vermont-specific rule addressing it, so it can only potentially be compounded lawfully by a licensed Vermont 503A pharmacy for a specific patient if it is on the FDA's permitted bulks list at the time, a status that has recently changed as the FDA removed it from a barred 'Category 2' listing in April 2026 while final compounding placement is still under review. [8] |
|---|---|
| Semaglutide/Tirzepatide (GLP-1 class) | Semaglutide and tirzepatide are legal in Vermont as prescription-only medicines when dispensed as FDA-approved brand products (e.g., Ozempic, Wegovy, Zepbound) or as compounded versions prepared in line with FDA guidance clarifying that the approved drugs' active ingredient is semaglutide in its base form. [10] |
| TB-500 | TB-500 has no Vermont-specific statute governing it and, like BPC-157, was previously barred from 503A compounding under the FDA's Category 2 bulks list before being removed from that category in April 2026, leaving its lawful compounding status in Vermont dependent on the FDA's ongoing federal review rather than any state rule. [11] |
| Human Growth Hormone (HGH/Somatropin) | No Vermont-specific statute singles out HGH/somatropin from general prescription-drug law, so it remains a prescription-only, FDA-approved drug in Vermont that is illegal to distribute or possess without a valid prescription under the general federal and Vermont pharmacy/drug framework administered by the Board of Pharmacy. [1] |
Sources
Last researched: 2026-09-09
Frequently asked questions
Can I buy peptides like BPC-157 in Vermont without a prescription?
No, you cannot lawfully buy peptides like BPC-157 for human use in Vermont without a prescription from a licensed provider filled through a compliant compounding pharmacy, because BPC-157 remains an unapproved new drug under federal law and Vermont has no separate rule permitting its sale as a research chemical or supplement. [7]
Can I bring peptides into Vermont from another state or import them for personal use?
Vermont has no specific personal-importation rule for peptides, so unapproved research peptides brought in for human use remain subject to the same federal unapproved-new-drug restrictions that apply everywhere in the U.S., while an FDA-approved peptide drug obtained under a valid prescription can generally be transported for personal medical use.
Can a Vermont telehealth provider prescribe semaglutide or compounded peptides?
Yes, a Vermont-licensed prescriber can prescribe FDA-approved GLP-1 drugs like semaglutide via telehealth, and compounded versions can be dispensed only by a 503A pharmacy operating within the federal framework the FDA clarified in its 2023 letter addressing the drugs' active ingredient during shortages. [10]
What are the penalties for selling unapproved peptides like BPC-157 in Vermont?
Selling unapproved peptides such as BPC-157 for human use can carry serious federal criminal exposure, as illustrated by a Kentucky compounding pharmacy and its owner who were federally charged and pleaded guilty to distributing unapproved new drugs including BPC-157, forfeiting over $1.7 million; Vermont sellers would face similar federal exposure plus potential Vermont Board of Pharmacy licensing action for any licensed pharmacy involved. [9]
Is TB-500 legal in Vermont?
TB-500 is not FDA-approved and has no Vermont-specific law addressing it directly, and although the FDA removed it from its restrictive 'Category 2' compounding bulks list in April 2026, its final eligibility for lawful compounding by a Vermont pharmacy remains under federal review rather than settled by any state rule. [11]